Medpace Holdings, Inc. (MEDP) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.76%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.76% | Share-based compensation / revenue. Period ending 2026-06-30. $21.21M ÷ $2.78B × 100 ≈ 0.76% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 2.78B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 21.21M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 583.40M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.78B | $21.21M | $583.40M | (m) | (m) | 0.76% | (m) | (m) |
| 2026-03-31 | (m) | $2.68B | $22.81M | $562.91M | (m) | (m) | 0.85% | (m) | (m) |
| 2025-12-31 | (m) | $2.53B | $34.79M | $534.93M | (m) | (m) | 1.37% | (m) | (m) |
| 2025-09-30 | (m) | $2.36B | $35.05M | $507.04M | (m) | (m) | 1.49% | (m) | (m) |
| 2025-06-30 | (m) | $2.23B | $40.46M | $477.51M | (m) | (m) | 1.81% | (m) | (m) |
| 2025-03-31 | (m) | $2.16B | $38.10M | $456.32M | (m) | (m) | 1.77% | (m) | (m) |
| 2024-12-31 | (m) | $2.11B | $25.51M | $446.87M | (m) | (m) | 1.21% | (m) | (m) |
| 2024-09-30 | (m) | $2.07B | $24.79M | $408.81M | (m) | (m) | 1.20% | (m) | (m) |
| 2024-06-30 | (m) | $2.03B | $18.07M | $381.45M | (m) | (m) | 0.89% | (m) | (m) |
| 2024-03-31 | (m) | $1.96B | $19.39M | $354.69M | (m) | (m) | 0.99% | (m) | (m) |
| 2023-12-31 | (m) | $1.89B | $20.52M | $336.82M | (m) | (m) | 1.09% | (m) | (m) |
| 2023-09-30 | (m) | $1.78B | $20.94M | $325.94M | (m) | (m) | 1.18% | (m) | (m) |
| 2023-06-30 | (m) | $1.67B | $21.73M | $318.86M | (m) | (m) | 1.30% | (m) | (m) |
| 2023-03-31 | (m) | $1.56B | $22.48M | $300.70M | (m) | (m) | 1.44% | (m) | (m) |
| 2022-12-31 | (m) | $1.46B | $21.41M | $278.70M | (m) | (m) | 1.47% | (m) | (m) |
| 2022-09-30 | (m) | $1.37B | $19.80M | $257.12M | (m) | (m) | 1.44% | (m) | (m) |
| 2022-06-30 | (m) | $1.29B | $18.05M | $233.01M | (m) | (m) | 1.40% | (m) | (m) |
| 2022-03-31 | (m) | $1.21B | $15.97M | $215.22M | (m) | (m) | 1.32% | (m) | (m) |
| 2021-12-31 | (m) | $1.14B | $14.47M | $198.62M | (m) | (m) | 1.27% | (m) | (m) |
| 2021-09-30 | (m) | $1.09B | $13.45M | $198.75M | (m) | (m) | 1.23% | (m) | (m) |
| 2021-06-30 | (m) | $1.03B | $12.16M | $191.46M | (m) | (m) | 1.18% | (m) | (m) |
| 2021-03-31 | (m) | $955.01M | $11.21M | $179.14M | (m) | (m) | 1.17% | (m) | (m) |
| 2020-12-31 | (m) | $925.92M | $13.78M | $167.04M | (m) | (m) | 1.49% | (m) | (m) |
| 2020-09-30 | (m) | $896.13M | $13.53M | $148.17M | (m) | (m) | 1.51% | (m) | (m) |
| 2020-06-30 | (m) | $882.00M | $20.23M | $131.74M | (m) | (m) | 2.29% | (m) | (m) |
| 2020-03-31 | (m) | $891.11M | $23.00M | $136.87M | (m) | (m) | 2.58% | (m) | (m) |
| 2019-12-31 | (m) | $860.97M | $20.74M | $127.26M | (m) | (m) | 2.41% | (m) | (m) |
| 2019-09-30 | (m) | $823.20M | $20.15M | $121.81M | (m) | (m) | 2.45% | (m) | (m) |
| 2019-06-30 | (m) | $786.21M | $12.11M | $118.74M | (m) | (m) | 1.54% | (m) | (m) |
| 2019-03-31 | (m) | $742.25M | $8.21M | $106.82M | (m) | (m) | 1.11% | (m) | (m) |
| 2018-12-31 | (m) | $704.59M | $6.50M | $101.05M | (m) | (m) | 0.92% | (m) | (m) |
| 2018-09-30 | (m) | $625.16M | $5.63M | $85.82M | (m) | (m) | 0.90% | (m) | (m) |
| 2018-06-30 | (m) | $556.55M | $5.18M | $76.10M | (m) | (m) | 0.93% | (m) | (m) |
| 2018-03-31 | (m) | (m) | $4.90M | $69.03M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $436.15M | $4.46M | $64.86M | (m) | (m) | 1.02% | (m) | (m) |
| 2017-09-30 | (m) | $431.71M | $4.47M | $62.31M | (m) | (m) | 1.04% | (m) | (m) |
| 2017-06-30 | (m) | $428.87M | $7.77M | $57.73M | (m) | (m) | 1.81% | (m) | (m) |
| 2017-03-31 | (m) | $428.61M | $9.84M | $55.56M | (m) | (m) | 2.30% | (m) | (m) |
| 2016-12-31 | (m) | $421.58M | $9.81M | $52.49M | (m) | (m) | 2.33% | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | $33.29M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | $27.04M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $359.06M | $22.32M | $20.56M | (m) | (m) | 6.22% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |